MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. (24th September 2021)
- Record Type:
- Journal Article
- Title:
- MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. (24th September 2021)
- Main Title:
- MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever
- Authors:
- Park, Carolin
Miranda-Garcia, María
Berendes, Rainer
Horneff, Gerd
Kuemmerle-Deschner, Jasmin
Ganser, Gerd
Huppertz, Hans-Iko
Minden, Kirsten
Haas, Johannes-Peter
Jansson, Annette F
Borte, Michael
Schuetz, Catharina
Oommen, Prasad
Frosch, Michael
Schlueter, Bernhard
Richter-Unruh, Annette
Kessel, Christoph
Hinze, Claas
Wittkowski, Helmut
Roth, Johannes
Foell, Dirk
Holzinger, Dirk - Abstract:
- Abstract: Objectives: Differential diagnosis in children with prolonged fever is challenging. In particular, differentiating systemic-onset JIA (SJIA) from infectious diseases is difficult. Biomarkers are needed that support the diagnostic work-up. The aim of this study was to validate the usefulness of Myeloid-related protein 8/14 (MRP8/14) measurements in the diagnostic work-up of febrile children and to transfer it to clinical practice. Methods: Data for 1110 paediatric patients were included and divided into two cohorts: (cohort A) for validation of MRP8/14 test performance with three different testing systems: the experimental ELISA, commercial ELISA and an innovative (point-of-care test) lateral flow immunoassay (LFIA); (cohort B) to validate the diagnostic accuracy with the two latter assays. Results: In cohort A ( n = 940), MRP8/14 was elevated in SJIA (12 110 ± 2650 ng/ml mean ± 95% CI) compared with other diagnoses (including infections and autoinflammatory diseases; 2980 ± 510 ng/ml) irrespective of fever and anti-inflammatory treatment ( P < 0.001). In untreated patients with fever ( n = 195) MRP8/14 levels in SJIA (19 740 ± 5080 ng/ml) were even higher compared with other diagnoses (4590 ± 1160 ng/ml) ( P < 0.001, sensitivity 73%, specificity 90%). In group B1, the performance of the tests was confirmed in untreated patients with fever ( n = 170): commercial ELISA (sensitivity 79%, specificity 89%) and LFIA (sensitivity 84%, specificity 81%). Compared withAbstract: Objectives: Differential diagnosis in children with prolonged fever is challenging. In particular, differentiating systemic-onset JIA (SJIA) from infectious diseases is difficult. Biomarkers are needed that support the diagnostic work-up. The aim of this study was to validate the usefulness of Myeloid-related protein 8/14 (MRP8/14) measurements in the diagnostic work-up of febrile children and to transfer it to clinical practice. Methods: Data for 1110 paediatric patients were included and divided into two cohorts: (cohort A) for validation of MRP8/14 test performance with three different testing systems: the experimental ELISA, commercial ELISA and an innovative (point-of-care test) lateral flow immunoassay (LFIA); (cohort B) to validate the diagnostic accuracy with the two latter assays. Results: In cohort A ( n = 940), MRP8/14 was elevated in SJIA (12 110 ± 2650 ng/ml mean ± 95% CI) compared with other diagnoses (including infections and autoinflammatory diseases; 2980 ± 510 ng/ml) irrespective of fever and anti-inflammatory treatment ( P < 0.001). In untreated patients with fever ( n = 195) MRP8/14 levels in SJIA (19 740 ± 5080 ng/ml) were even higher compared with other diagnoses (4590 ± 1160 ng/ml) ( P < 0.001, sensitivity 73%, specificity 90%). In group B1, the performance of the tests was confirmed in untreated patients with fever ( n = 170): commercial ELISA (sensitivity 79%, specificity 89%) and LFIA (sensitivity 84%, specificity 81%). Compared with ferritin, IL-18, ESR, soluble IL-2 receptor and procalcitonin, MRP8/14 showed the best accuracy. Conclusion: MRP8/14 serum analyses have been validated as a helpful tool supporting the diagnosis of SJIA in febrile children. The results could be confirmed with commercial ELISA and LFIA enabling a rapid diagnostic point-of-care screening test. … (more)
- Is Part Of:
- Rheumatology. Volume 61:Number 7(2022)
- Journal:
- Rheumatology
- Issue:
- Volume 61:Number 7(2022)
- Issue Display:
- Volume 61, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 61
- Issue:
- 7
- Issue Sort Value:
- 2022-0061-0007-0000
- Page Start:
- 3082
- Page End:
- 3092
- Publication Date:
- 2021-09-24
- Subjects:
- MRP8/14 -- fever -- diagnosis -- biomarker -- validation -- point-of-care test -- autoinflammation -- infection
Rheumatism -- Periodicals
Rheumatology -- Periodicals
616.723005 - Journal URLs:
- http://rheumatology.oupjournals.org ↗
http://rheumatology.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1093/rheumatology/keab729 ↗
- Languages:
- English
- ISSNs:
- 1462-0324
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7960.731900
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22291.xml